1,211,617 Shares in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Acquired by Acadian Asset Management LLC

Acadian Asset Management LLC acquired a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) in the 2nd quarter, Holdings Channel.com reports. The fund acquired 1,211,617 shares of the company’s stock, valued at approximately $2,300,000.

Other institutional investors have also recently modified their holdings of the company. Quest Partners LLC acquired a new position in shares of Amylyx Pharmaceuticals during the 4th quarter worth approximately $89,000. Allspring Global Investments Holdings LLC raised its position in shares of Amylyx Pharmaceuticals by 52,575.9% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 15,276 shares of the company’s stock worth $43,000 after purchasing an additional 15,247 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Amylyx Pharmaceuticals during the 4th quarter worth approximately $408,000. CWM LLC raised its holdings in Amylyx Pharmaceuticals by 104.2% in the 2nd quarter. CWM LLC now owns 28,643 shares of the company’s stock valued at $54,000 after acquiring an additional 14,613 shares during the last quarter. Finally, SG Americas Securities LLC raised its holdings in Amylyx Pharmaceuticals by 113.6% in the 2nd quarter. SG Americas Securities LLC now owns 55,836 shares of the company’s stock valued at $106,000 after acquiring an additional 29,697 shares during the last quarter. 95.84% of the stock is currently owned by institutional investors and hedge funds.

Amylyx Pharmaceuticals Stock Up 5.2 %

Shares of NASDAQ AMLX opened at $2.62 on Friday. Amylyx Pharmaceuticals, Inc. has a 52-week low of $1.58 and a 52-week high of $20.44. The firm has a fifty day moving average of $2.12 and a 200-day moving average of $3.06. The stock has a market capitalization of $178.37 million, a PE ratio of -2.45 and a beta of -0.62.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.35). Amylyx Pharmaceuticals had a negative net margin of 17.86% and a negative return on equity of 15.51%. The company had revenue of ($1.02) million for the quarter, compared to analysts’ expectations of $18.83 million. During the same period in the prior year, the firm earned $0.31 earnings per share. Equities research analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.27 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. The Goldman Sachs Group boosted their price target on Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the company a “neutral” rating in a report on Friday, July 12th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Amylyx Pharmaceuticals in a report on Wednesday, July 10th. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $17.60.

Insider Buying and Selling

In other Amylyx Pharmaceuticals news, Director George M. Milne, Jr. purchased 100,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was purchased at an average cost of $2.20 per share, with a total value of $220,000.00. Following the transaction, the director now owns 858,571 shares in the company, valued at $1,888,856.20. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 11.70% of the stock is owned by corporate insiders.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.